Anthropic has announced the progress made by its large-scale model, Claude, in the research on designing proteins that counteract scorpion venom. Within a mere 64 hours, Claude generated over 310,000 protein design proposals. Following screening and validation processes, 17 candidate proteins were identified that are capable of binding to specific neurotoxins found in scorpion venom. Notably, two of these candidates, designed to target the Cn2 toxin, exhibited binding affinity at the nanomolar level, suggesting significant potential for further exploration. In this study, Claude autonomously executed multiple tasks, including tool invocation, structural prediction, and proposal refinement, thereby encompassing a more thorough scientific research workflow for protein design. Concurrently, several companies have recently achieved notable advancements in AI-driven drug development: Radical Numerics has introduced a genomic large model, and its AI-designed phage has received approval for compassionate use in patients suffering from drug-resistant bacterial infections. OpenAI, on the other hand, has acquired the biopharmaceutical AI firm Orchestra Bio and integrated its technology into a life sciences platform, aiming to enhance the application of AI in project coordination and management throughout the drug development lifecycle. At present, the exploration of AI across various stages of biopharmaceutical research is still in its nascent stages, and extensive validation is necessary before safe and effective treatment options can be developed.